Cargando…
2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae
BACKGROUND: Colistin is considered as one of the last resort of antibiotics against carbapenem-resistant enterobacteriaceae. During the last decade, increased use of colistin or polymyxins due to the increasing prevalence of carbapenem-resistant Gram-negative bacteria has unfortunately led to the em...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253246/ http://dx.doi.org/10.1093/ofid/ofy210.2099 |
_version_ | 1783373453728940032 |
---|---|
author | Ahmed, Sara Mahmood, Syed Faisal Sharif, Fatima Aijaz, Mariam Awan, Safia Jamil, Bushra |
author_facet | Ahmed, Sara Mahmood, Syed Faisal Sharif, Fatima Aijaz, Mariam Awan, Safia Jamil, Bushra |
author_sort | Ahmed, Sara |
collection | PubMed |
description | BACKGROUND: Colistin is considered as one of the last resort of antibiotics against carbapenem-resistant enterobacteriaceae. During the last decade, increased use of colistin or polymyxins due to the increasing prevalence of carbapenem-resistant Gram-negative bacteria has unfortunately led to the emergence of colistin-resistant strains. There are no defined antibiotic regimens for colistin-resistant strains which makes the treatment of these organisms extremely challenging. We therefore report the clinical spectrum and outcomes of infections due to colistin-resistant carbapenem-resistant Enterobacteriaceae (Co-CRE) as well as the factors associated with acquisition of co-CRE. METHODS: We conducted a retrospective cross-sectional study from January 2013 till December 2017 on patients admitted to a tertiary care hospital in Karachi, Pakistan. Statistical analysis was done using SPSS 19. RESULTS: Forty patients with Co-CRE were identified of which 29 (72.5%) were males. Median age was 54.5 years. The most common organism isolated was Klebsiella in 22 (55%) followed by Providencia in 5 (12.5%) patients. Most common source of infection was the lung in 12 (30%) followed by urine in 11 (27.5%) patients. Similarly, the most common cause of bacteremia was pneumonia followed by intra-abdominal infections (50% and 37.5% of bacteremia cases, respectively). Twenty-eight (70%) patients had prior cultures with multi-drug-resistant organisms and 36 (90%) had used antibiotics in the past. A quarter (10) patients had pan resistant co-CRE strains while of the remaining strains 66% were sensitive to Fosfomycin. All patients received Colistin-based regimen in combination with 2 or 3 of the following: carbapenem, Fosfomycin, Amikacin, co-triamoxazole, and tigecycline. Complete clinical cure was achieved in only 50% of patients whereas microbiological eradication was achieved in 75%. Higher PITT bacteremia score, solid-organ transplant, and acute kidney injury were associated with mortality in patients with co-CRE. CONCLUSION: Infections with co-CRE was seen in patients with prior nosocomial exposures and led to poor outcomes, despite combination treatment guided by susceptibilities. DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6253246 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62532462018-11-28 2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae Ahmed, Sara Mahmood, Syed Faisal Sharif, Fatima Aijaz, Mariam Awan, Safia Jamil, Bushra Open Forum Infect Dis Abstracts BACKGROUND: Colistin is considered as one of the last resort of antibiotics against carbapenem-resistant enterobacteriaceae. During the last decade, increased use of colistin or polymyxins due to the increasing prevalence of carbapenem-resistant Gram-negative bacteria has unfortunately led to the emergence of colistin-resistant strains. There are no defined antibiotic regimens for colistin-resistant strains which makes the treatment of these organisms extremely challenging. We therefore report the clinical spectrum and outcomes of infections due to colistin-resistant carbapenem-resistant Enterobacteriaceae (Co-CRE) as well as the factors associated with acquisition of co-CRE. METHODS: We conducted a retrospective cross-sectional study from January 2013 till December 2017 on patients admitted to a tertiary care hospital in Karachi, Pakistan. Statistical analysis was done using SPSS 19. RESULTS: Forty patients with Co-CRE were identified of which 29 (72.5%) were males. Median age was 54.5 years. The most common organism isolated was Klebsiella in 22 (55%) followed by Providencia in 5 (12.5%) patients. Most common source of infection was the lung in 12 (30%) followed by urine in 11 (27.5%) patients. Similarly, the most common cause of bacteremia was pneumonia followed by intra-abdominal infections (50% and 37.5% of bacteremia cases, respectively). Twenty-eight (70%) patients had prior cultures with multi-drug-resistant organisms and 36 (90%) had used antibiotics in the past. A quarter (10) patients had pan resistant co-CRE strains while of the remaining strains 66% were sensitive to Fosfomycin. All patients received Colistin-based regimen in combination with 2 or 3 of the following: carbapenem, Fosfomycin, Amikacin, co-triamoxazole, and tigecycline. Complete clinical cure was achieved in only 50% of patients whereas microbiological eradication was achieved in 75%. Higher PITT bacteremia score, solid-organ transplant, and acute kidney injury were associated with mortality in patients with co-CRE. CONCLUSION: Infections with co-CRE was seen in patients with prior nosocomial exposures and led to poor outcomes, despite combination treatment guided by susceptibilities. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253246/ http://dx.doi.org/10.1093/ofid/ofy210.2099 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Ahmed, Sara Mahmood, Syed Faisal Sharif, Fatima Aijaz, Mariam Awan, Safia Jamil, Bushra 2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae |
title | 2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae |
title_full | 2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae |
title_fullStr | 2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae |
title_full_unstemmed | 2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae |
title_short | 2446. Clinical Spectrum and Outcomes of Colistin-Resistant Carbapenem-Resistant Enterobacteriaceae |
title_sort | 2446. clinical spectrum and outcomes of colistin-resistant carbapenem-resistant enterobacteriaceae |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253246/ http://dx.doi.org/10.1093/ofid/ofy210.2099 |
work_keys_str_mv | AT ahmedsara 2446clinicalspectrumandoutcomesofcolistinresistantcarbapenemresistantenterobacteriaceae AT mahmoodsyedfaisal 2446clinicalspectrumandoutcomesofcolistinresistantcarbapenemresistantenterobacteriaceae AT shariffatima 2446clinicalspectrumandoutcomesofcolistinresistantcarbapenemresistantenterobacteriaceae AT aijazmariam 2446clinicalspectrumandoutcomesofcolistinresistantcarbapenemresistantenterobacteriaceae AT awansafia 2446clinicalspectrumandoutcomesofcolistinresistantcarbapenemresistantenterobacteriaceae AT jamilbushra 2446clinicalspectrumandoutcomesofcolistinresistantcarbapenemresistantenterobacteriaceae |